Quark Pharmaceuticals

Quark Pharmaceuticals is a clinical-stage pharmaceutical company founded in 1993, headquartered in Fremont, California, with research and development facilities in Boulder, Colorad

o, and Ness Ziona, Israel. The company specializes in developing RNA interference (RNAi)-based therapeutics, particularly small interfering RNA (siRNA) drugs, aimed at treating chronic and acute diseases with unmet medical needs. Recognized as a leader in RNAi discovery, Quark holds the largest clinical-stage siRNA pipeline in the industry. Its proprietary BiFAR technology platform supports high-throughput gene inactivation and functional gene identification. Quark's pipeline includes two primary product candidates, QPI-1002 and QPI-1007, both in pivotal Phase III clinical studies targeting kidney protection and neuroprotection in ophthalmology, respectively. The company collaborates with large pharmaceutical partners and conducts clinical studies globally, including partnerships in China and India.